Lumexa Imaging Holdings share price today

Lumexa Imaging Holdings, Inc.'s share price was $13.10 at the close on 4 November 2026. That is 18.6% above its average price over the last 200 trading days. Since its first close in our records, on 12 December 2025, it has traded between $7 and $19, and at that close it sat 53% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row.

Over the last 11 months the share price moved −29% while the S&P 500 moved +12%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Lumexa Imaging Holdings, Inc. pays no dividend. In the last 6 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Lumexa Imaging Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Lumexa Imaging Holdings, Inc. earned $2.7 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $47.1 M. That is 1.0% of the quarter's revenue. The same quarter a year earlier lost $7.7 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Lumexa Imaging Holdings, Inc. reported $264 M of revenue in the Jun 2026 quarter, +5.1% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 2 years it has grown 4.6% a year on average. The last full year, FY25, came in at $1.0 B.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $1.0 B, +7.8% on the year before.

Recent pace: the last four quarters grew +5.4% on average, against 4.6% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

Lumexa Imaging Holdings, Inc.'s operating margin was 3.2% in the Jun 2026 quarter, 3.5 percentage points lower than the same quarter a year ago. Over the last four quarters it has moved −3.3 percentage points. Across 3 years it has been between −0.6% and 5.0%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed −0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Lumexa Imaging Holdings, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $17.1 M of operating cash against −$47.1 M of profit. After $23.5 M of spending on assets, free cash was −$6.4 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Lumexa Imaging Holdings, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $75.3 M on assets over the last 3 years. Averaged over those years that is 2.5% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $75.3 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Lumexa Imaging Holdings, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Lumexa Imaging Holdings, Inc. at 1.2× its FY25 revenue of $1.0 B. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Lumexa Imaging Holdings, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Lumexa Imaging Holdings, Inc. earned a ROE of −8% in FY25. That is up from a low of −62% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −4.6% net margin and 0.58× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −4.6% net margin × 0.58× asset turnover × 3.01× leverage (assets divided by equity) ≈ −8.0% on equity. The margin does its share; borrowing is a big part of it.

Lumexa Imaging Holdings, Inc. has total debt of $975 M against shareholder equity of $615 M as of Jun 2026, so its debt is 1.59× its equity. Year by year, that ratio went from 6.58 in FY23 to 1.64 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

8.7% of Lumexa Imaging Holdings, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Lumexa Imaging Holdings, Inc., the Z-score is 0.79. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 0.79 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Lumexa Imaging Holdings, Inc. is not among the largest members shown in this industry comparison for Medical Devices.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Lumexa Imaging Holdings is the 35th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Tandem Diabetes Care, Inc., Artivion, Inc. and Alphatec Holdings, Inc. Just below it: PROCEPT BioRobotics Corporation, Avanos Medical, Inc. and Integra LifeSciences Holdings Corporation.

Medical Devices companies close in size

32. Tandem Diabetes Care, Inc. $1.3 billion
33. Artivion, Inc. $1.3 billion
34. Alphatec Holdings, Inc. $1.3 billion
35. Lumexa Imaging Holdings, Inc. $1.3 billion
36. PROCEPT BioRobotics Corporation $1.2 billion
37. Avanos Medical, Inc. $1.2 billion
38. Integra LifeSciences Holdings Corporation $1.2 billion

All 75 Medical Devices companies, largest first

Companies close in size in other industries

2295. Ichor Holdings, Ltd. $1.3 billion · Semiconductor Equipment & Materials
2296. MannKind Corporation $1.3 billion · Biotechnology
2297. Lumexa Imaging Holdings, Inc. $1.3 billion
2298. Leggett & Platt, Incorporated $1.3 billion · Furnishings, Fixtures & Appliances
2299. Trump Media & Technology Group Corp. $1.2 billion · Internet Content & Information

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.